Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 13, 2007

ChemDiv to Provide Merck With Discovery Chemistry in Multiyear Agreement

  • Merck extended it’s partnership with ChemDiv until 2009 to provide discovery libraries of lead-like small molecules. The new agreement expands the collaboration that has been going on for the last three years, and roughly doubles the FTE effort at ChemDiv's Chemical Diversity Research Institute in Moscow.

    "This new agreement reflects the success of our previous relationship and our high esteem for the quality of ChemDiv's discovery and synthesis capabilities," says Peter Raddatz, vp of medicinal chemistry at Merck. "ChemDiv will continue to complement our in-house activities to add further diversity and novelty to Merck's discovery projects."

    A steering committee with representatives from Merck and ChemDiv will determine projects to be produced by ChemDiv for early-stage discovery at Merck. Promising hits will then be further optimized and placed into Merck's discovery pipeline.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »